DB
Dren Bio
United States · Biotech
Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.
Product
The clinical-stage biotechnology company advances investigational medicines through clinical studies. Its pipeline includes dibotatug and programmes built on a platform designed to engage myeloid cells in clearing disease-related targets.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Private financing | $350M | Juvia Group — LeadLightspeed — Lead8VC — ParticipantAisling Capital — ParticipantArrowMark Partners — ParticipantBVF Partners — ParticipantCormorant Asset Management — ParticipantGeneral Catalyst — ParticipantHBM Healthcare Investments — ParticipantMirae Asset Capital Life Science — ParticipantMission BioCapital — ParticipantOrbiMed — ParticipantSR One — ParticipantTaiho Ventures — Participant |